Jennison Associates LLC filed an amended Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership of 1,101,652 shares of Palvella Therapeutics Inc common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Jennison Associates LLC reported aggregate beneficial ownership of 1,101,652 shares of Palvella Therapeutics Inc common stock.
  • Percent of class: The filing discloses that the position represents 7.7% of the class of securities.
  • Sole voting power: Jennison Associates holds sole voting power over all 1,101,652 shares.
  • Shared dispositive power: The filing reports shared dispositive power over all 1,101,652 shares, with sole dispositive power of 0.
  • Triggering event date: The date of the event requiring the filing is stated as September 30, 2026.
  • Filer classification: Jennison Associates LLC is identified as an investment adviser (type "IA"), organized in Delaware, with a principal office at 55 East 52nd Street, New York, NY 10055.

Jennison Associates LLC Discloses Amended Ownership Position in Palvella Therapeutics

According to the filing, Jennison Associates LLC submitted Amendment No. 1 to a Schedule 13G in connection with its holdings in Palvella Therapeutics Inc (NASDAQ:PVLA), whose principal executive offices are listed at 353 W. Lancaster Avenue, Suite 200, Wayne, PA 19087. The CUSIP number for the common stock is reported as 697947109. The event triggering the filing occurred on September 30, 2026, and the statement was signed on October 28, 2026, by Beata Markowicz, Senior Vice President, Compliance.

The filing reports that Jennison Associates beneficially owns 1,101,652 shares, representing 7.7% of the outstanding class. Of that total, the firm holds sole voting power over all 1,101,652 shares and shared dispositive power over the same amount, while sole dispositive power is reported as zero. Shared voting power is also reported as zero.

The filing includes the standard Schedule 13G certification, stating that, according to Jennison Associates, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." Items covering ownership of 5% or less of a class, ownership on behalf of another person, subsidiary identification, and group membership are each designated as "Not Applicable" in the filing.

What Was Disclosed

Jennison Associates LLC filed an amended Schedule 13G disclosing a 7.7% beneficial ownership stake of 1,101,652 shares of Palvella Therapeutics Inc common stock, with sole voting power and shared dispositive power over the full position, as of September 30, 2026.